Revolutionizing Diaphragm Monitoring for Critical Care

RESPINOR's DXT is a novel, non-invasive ultrasound-based medical device. Applicable in critical care for accurate and continuous diaphragm monitoring, for early detection of diaphragm dysfunction. Secured substantial funding from H2020 and The Research Council of Norway. EN ISO 13485:2016 certified. Successfully completed clinical evidence studies for the first patient segment, mechanical ventilation (MV). Working towards regulatory submission in both EU and the US. DXT offers a huge market potential with >350m patients in US/EU. Our vision is to make diaphragm monitoring the next vital sign for assessing work of breathing.

What is DXT?

DXT, or Diaphragm Excursion Technology, is a groundbreaking non-invasive medical device developed by RESPINOR that utilizes ultrasound for continuous monitoring of the diaphragm, the main breathing muscle, in critically ill patients. This technology aids in the early detection of diaphragm dysfunction and enhances clinical decision-making in critical care settings.

Product: RESPINOR DXT is a medical technology designed to provide an objective measure of diaphragm function.
Purpose: DXT aims to optimize extubation timing, reduce re-intubation rates, improve patient outcomes, and thereby lower healthcare costs.
Technology: DXT uses sensors with optimized design for patient comfort, continuous monitoring, and computer-aided sensor placement.
Non-Invasive: DXT offers a non-invasive solution for monitoring diaphragm function.
Actionable Output: DXT provides actionable output, to detect patients at increased risk of reintubation during the weaning process from MV. DXT measures diaphragm excursion (DE) and respiratory rate (RR) in real-time including trends.
Medical Need: DXT addresses the need for accurate and cost-effective solutions for monitoring diaphragm function, as diaphragm dysfunction is often under-recognized, and reintubation poses risks to patients and increased healthcare costs.
Learn more

Recent updates from RESPINOR

July 16, 2024

Operator independent continuousultrasound monitoring of diaphragm excursionpredicts successful weaning from mechanicalventilation: a prospective observational study, Demoule et al. Critical Care (2024) 28:245.

RESPINOR has successfully completed the clinical evidence program for the first indication, weaning from mechanical ventilation (MV), and is now preparing for regulatory submission both in Europe and the US.
Read more
July 21, 2023

RESPINOR announces new Chair of the Board

On July 21, 2023, RESPINOR AS, a clinical-stage medical device company, appointed Anders Wold as Chair of the Board, effective immediately. Wold brings four decades of healthcare and ultrasound industry leadership to the role, having previously served as President and CEO of GE Healthcare Clinical Care Solutions. The current Chair, Aage Bryn, will become a Board member, while the rest of the Board will maintain their positions. Wold's expertise in the ultrasound business and international MedTech connections will support RESPINOR in commercializing and launching their innovative DXT product. Wold expressed enthusiasm for joining RESPINOR and looks forward to addressing unmet clinical needs in respiratory care.
Read more
December 9, 2022

First patient included in the multicenter, multinational DE-RISK WF II study in Europe

The first patient has been successfully included in the DE-RISK WF II study at the coordinating center, Hôpitaux Universitaires Pitié Salpêtrière, in Paris.
Read more
January 4, 2022

RESPINOR is strengthening the team preparing for commercialization of DXT

Meet Magdalena K. Gjefle, our new Director of Business Development, and Tristan Hollande, our CTO at RESPINOR. Magdalena, with 30 years of experience in business development, finance, and the pharma/biotech sector, holds advanced degrees from prestigious institutions. She's joined us from Inven2 and Weifa. Tristan, an engineer with over two decades of experience in sensor measurements, maps, and GPS-related software, has successfully led R&D projects. Visit their LinkedIn profiles for more information.
Read more
October 15, 2021

RESPINOR AS Successfully completed Private Placement of approx. NOK 20 million (€ 2,0 million)

The Company's Board of Directors is pleased to announce the successful completion of a Private Placement, led by our financial advisor, Corpura Fondkommission AB, raising approximately NOK 20 million (€2.0 million) in gross proceeds. These funds will support the ongoing clinical study DE-RISK WF in France, Italy, and Norway, as well as the continued development of the DXT product, aiming for a design freeze and CE mark submission for a Q4-2022 product launch. We are also partnering with Corpura Fondkommission for our financial advisory needs and plan to list the Company's shares on a Swedish stock exchange in early 2022.
Read more
Update cookies preferences